ADMA - ADMA Biologics Inc Stock Price, Fair Value and News

9.14USD+0.35 (+3.98%)Market Closed

Market Summary

USD9.14+0.35

Market Closed

3.98%

ADMA Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)

ADMA Stock Price

View Fullscreen

ADMA RSI Chart

ADMA Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-559.14

Price/Sales (Trailing)

7.2

EV/EBITDA

119.48

Price/Free Cashflow

126.32

ADMA Price/Sales (Trailing)

ADMA Profitability

Operating Margin

39.39%

EBT Margin

-6.35%

Return on Equity

-2.37%

Return on Assets

-1.04%

Free Cashflow Yield

0.79%

ADMA Fundamentals

ADMA Revenue

Revenue (TTM)

283.2M

Rev. Growth (Yr)

43.86%

Rev. Growth (Qtr)

10.79%

ADMA Earnings

Earnings (TTM)

-3.6M

Earnings Growth (Yr)

362.28%

Earnings Growth (Qtr)

200.92%

Breaking Down ADMA Revenue

Last 7 days

26.9%

Last 30 days

45.7%

Last 90 days

69.6%

Trailing 12 Months

107.8%

How does ADMA drawdown profile look like?

ADMA Financial Health

Current Ratio

5.21

ADMA Investor Care

Shares Dilution (1Y)

4.29%

Diluted EPS (TTM)

-0.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	283.2M	0	0	0
2023	181.9M	208.1M	234.3M	258.2M
2022	122.6M	138.7M	159.1M	154.1M
2021	48.1M	58.1M	68.5M	109.6M
2020	36.2M	37.0M	40.1M	42.2M
2019	16.5M	18.8M	21.8M	29.6M
2018	24.2M	25.4M	24.9M	17.0M
2017	11.2M	12.3M	14.1M	22.8M
2016	7.8M	8.8M	9.8M	10.7M
2015	5.9M	5.7M	6.2M	7.2M
2014	3.8M	4.6M	4.9M	5.9M
2013	1.9M	2.4M	3.2M	3.1M
2012	1.7M	1.5M	1.3M	1.1M
2011	0	0	0	1.9M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of ADMA Biologics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	kestenberg-messina kaitlin m.	acquired	-	-	192,320	coo and svp, compliance
Mar 31, 2024	kestenberg-messina kaitlin m.	sold (taxes)	-13,761	6.6	-2,085	coo and svp, compliance
Mar 31, 2024	grossman adam s	sold (taxes)	-143,563	6.6	-21,752	president,ceo, and interim cfo
Mar 19, 2024	elms steve	sold	-2,503,920	6.08	-411,829	-
Mar 18, 2024	elms steve	sold	-299,821	6.01	-49,887	-
Mar 15, 2024	elms steve	sold	-1,099,880	6.01	-183,008	-
Mar 14, 2024	elms steve	sold	-2,712,070	6.05	-448,276	-
Mar 13, 2024	elms steve	sold	-2,527,470	6.21	-407,000	-
Mar 07, 2024	grossman adam s	sold (taxes)	-177,180	6.16	-28,763	president and ceo
Mar 07, 2024	lenz brian	sold (taxes)	-104,504	6.16	-16,965	evp, cfo

Which funds bought or sold ADMA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	89.71	8,464,000	13,246,000	0.02%
May 13, 2024	Key Financial Inc	unchanged	-	1,560	4,950	-%
May 13, 2024	Rafferty Asset Management, LLC	added	25.34	2,042,490	4,502,950	0.02%
May 13, 2024	Caligan Partners LP	sold off	-100	-2,138,350	-	-%
May 13, 2024	XTX Topco Ltd	reduced	-36.81	-59,059	705,151	0.10%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	3.4	10,713,700	31,724,700	-%
May 13, 2024	FMR LLC	added	9.1	10,137	27,232	-%
May 13, 2024	Continuum Advisory, LLC	new	-	2,841	2,841	-%
May 13, 2024	EAM Global Investors LLC	new	-	5,092,320	5,092,320	1.18%
May 13, 2024	STRS OHIO	added	117	507,000	739,000	-%

Are Funds Buying or Selling ADMA?

Are funds buying ADMA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADMA

No. of Funds

Unveiling ADMA Biologics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	teachers advisors, llc	2.17%	4,955,411	SC 13G/A
Mar 11, 2024	tiaa cref investment management llc	2.17%	4,955,411	SC 13G/A
Mar 11, 2024	nuveen asset management, llc	2.17%	4,955,411	SC 13G/A
Feb 14, 2024	nuveen asset management, llc	2.24%	5,062,545	SC 13G
Feb 14, 2024	teachers advisors, llc	2.24%	5,062,545	SC 13G
Feb 14, 2024	tiaa cref investment management llc	2.24%	5,062,545	SC 13G
Feb 14, 2024	perceptive advisors llc	2.8%	6,433,369	SC 13G/A
Feb 13, 2024	vanguard group inc	5.71%	12,891,875	SC 13G
Jan 26, 2024	blackrock inc.	7.9%	17,917,745	SC 13G/A
Feb 14, 2023	nuveen asset management, llc	2.48%	5,483,369	SC 13G/A

Recent SEC filings of ADMA Biologics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	DEFA14A	DEFA14A
Apr 02, 2024	3	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to ADMA Biologics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	19.54%	-2.80%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	206.31%	55.15%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	5.07%	336.18%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.08%	29.79%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-10.40%	79.21%	-0.7	7.61	-13.45%	69.54%

ADMA Biologics Inc News

Latest updates

ADMA Biologics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	10.8%	81,875	73,904	67,275	60,123	56,914	49,982	41,090	33,905	29,103	55,000	20,681	17,831	16,049	13,956	10,276	7,788	10,200	11,818	7,223	7,000	3,529
Cost Of Revenue	-0.1%	42,767	42,817	42,622	43,433	40,401	35,805	31,433	26,136	25,441	22,872	20,295	18,833	17,770	19,111	11,855	13,496	16,829	11,692	7,916	10,491	9,405
Gross Profit	25.8%	39,108	31,086	24,653	16,690	16,513	14,177	9,657	7,769	3,662	3,511	385	-1,002	-1,721	-	-	-	-	-	-	-	-
Operating Expenses	2.6%	17,287	16,853	15,967	17,163	17,326	20,235	18,973	16,944	18,477	16,703	14,822	14,579	13,443	-30,115	24,077	24,911	26,970	19,864	16,273	17,900	16,737
S&GA Expenses	0.7%	15,639	15,535	14,726	14,248	14,512	13,895	12,893	11,970	13,700	11,698	10,727	10,438	10,034	9,300	9,116	8,703	7,932	7,032	7,197	6,086	5,595
R&D Expenses	1.0%	450	445	596	1,403	855	1,075	1,042	873	624	729	771	1,159	988	1,013	1,708	1,656	1,529	465	491	517	871
EBITDA Margin	-22.2%	0.05*	0.06*	0.06*	0.07*	0.06*	0.05*	0.04*	0.02*	0.01*	0.01*	0.00*	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-39.4%	3,769	6,215	6,398	6,299	6,115	5,737	5,580	4,573	3,389	3,316	3,299	3,247	3,196	3,109	3,091	3,067	2,717	2,731	2,649	2,073	1,541
Earnings Before Taxes	-	18,401	-	-	-	-6,789	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	8.8%	-0.06*	-0.07*	-0.08*	-0.09*	-0.10*	-0.12*	-0.11*	-0.13*	-0.15*	-0.16*	-0.26*	-	-	-	-	-	-	-	-	-	-
Net Income	200.9%	17,806	-17,644	2,565	-6,370	-6,788	-12,231	-14,899	-13,764	-25,007	-16,649	-17,712	-18,905	-18,379	-19,407	-16,917	-20,178	-19,245	-10,561	-11,438	-13,211	-13,067
Net Income Margin	88.2%	-0.01*	-0.11*	-0.10*	-0.19*	-0.26*	-0.43*	-0.44*	-0.53*	-0.64*	-0.65*	-1.09*	-1.27*	-	-	-	-	-	-	-	-	-
Free Cashflow	-127.8%	-4,565	16,399	11,229	-6,931	-16,666	-11,127	-16,665	-16,770	-28,855	-37,140	-16,201	-36,737	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	6.6%	351	329	349	343	341	348	301	297	308	276	239	233	236	208	190	192	211	127	138	143	78.00
Current Assets	7.6%	276	257	274	266	264	270	224	223	240	209	175	171	177	154	140	143	165	86.00	97.00	104	38.00
Cash Equivalents	-11.7%	45.00	51.00	74.00	63.00	69.00	87.00	35.00	52.00	70.00	51.00	34.00	42.00	62.00	56.00	60.00	76.00	101	27.00	48.00	74.00	17.00
Inventory	2.8%	178	173	163	162	164	163	163	146	139	125	114	100	94.00	82.00	70.00	56.00	52.00	53.00	40.00	24.00	18.00
Net PPE	2.8%	55.00	54.00	55.00	56.00	57.00	58.00	57.00	55.00	53.00	51.00	48.00	46.00	44.00	42.00	40.00	37.00	35.00	32.00	31.00	29.00	30.00
Goodwill	0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	1.6%	197	194	198	196	195	196	200	183	181	135	136	121	123	119	119	115	114	101	102	96.00	68.00
Current Liabilities	6.6%	53.00	50.00	42.00	42.00	37.00	39.00	44.00	28.00	32.00	30.00	32.00	18.00	21.00	20.00	16.00	13.00	14.00	14.00	15.00	10.00	8.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	13.7%	154	135	151	147	146	152	100	114	127	141	103	112	113	88.00	71.00	77.00	96.00	26.00	36.00	47.00	10.00
Retained Earnings	3.5%	-488	-506	-488	-491	-484	-478	-465	-450	-437	-412	-395	-377	-358	-340	-321	-304	-283	-264	-254	-242	-229
Additional Paid-In Capital	0.1%	642	641	640	638	630	630	566	565	564	553	498	489	471	429	392	381	380	291	290	290	240
Shares Outstanding	2.5%	232	226	226	225	222	222	196	196	196	140	134	127	116	-	-	-	-	-	-	-	-
Float	-	-	-	-	794	-	-	-	373	-	-	-	173	-	-	-	184	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-112.6%	-2,218	17,596	11,985	-6,058	-14,722	-7,379	-13,284	-12,830	-26,013	-33,465	-13,412	-32,262	-33,229	-32,219	-23,852	-21,284	-24,646	-19,652	-23,630	-18,623	-14,287
Share Based Compensation	22.7%	2,141	1,745	1,695	1,637	1,110	1,069	1,313	1,191	1,641	1,213	688	805	781	688	775	716	677	636	651	727	637
Cashflow From Investing	-67.8%	-2,362	-1,407	-756	-872	-1,944	-3,748	-3,380	-3,940	-2,842	-3,675	-2,788	-4,475	-2,571	-3,598	-2,885	-4,168	-2,072	-1,594	-1,971	-135	-110
Cashflow From Financing	96.3%	-1,447	-38,993	415	240	-650	62,744	-843	-319	47,271	53,819	8,203	17,181	41,845	32,064	10,631	-1.69	101,203	-7.68	-7.56	75,841	4,177

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ADMA Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
REVENUES	$ 81,875	$ 56,914
Cost of product revenue	42,767	40,401
Gross profit	39,108	16,513
OPERATING EXPENSES:
Research and development	450	855
Plasma center operating expenses	1,005	1,780
Amortization of intangible assets	193	179
Selling, general and administrative	15,639	14,512
Total operating expenses	17,287	17,326
INCOME (LOSS) FROM OPERATIONS	21,821	(813)
OTHER INCOME (EXPENSE):
Interest income	384	166
Interest expense	(3,769)	(6,115)
Other expense	(35)	(27)
Other expense, net	(3,420)	(5,976)
INCOME (LOSS) BEFORE INCOME TAXES	18,401	(6,789)
Provision for income taxes	595	0
NET INCOME (LOSS)	$ 17,806	$ (6,789)
BASIC EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)	$ 0.08	$ (0.03)
DILUTED EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)	$ 0.08	$ (0.03)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (in shares)	228,874,847	221,921,750
Diluted (in shares)	236,414,374	221,921,750

ADMA Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 45,325	$ 51,352
Accounts receivable, net	49,621	27,421
Inventories	177,732	172,906
Prepaid expenses and other current assets	3,741	5,334
Total current assets	276,419	257,013
Property and equipment, net	55,317	53,835
Intangible assets, net	321	499
Goodwill	3,530	3,530
Right-to-use assets	9,397	9,635
Deposits and other assets	5,891	4,670
TOTAL ASSETS	350,875	329,182
Current liabilities:
Accounts payable	17,186	15,660
Accrued expenses and other current liabilities	33,691	32,919
Current portion of deferred revenue	1,118	182
Current portion of lease obligations	1,093	1,045
Total current liabilities	53,088	49,806
Senior notes payable, net of discount	130,847	130,594
Deferred revenue, net of current portion	1,654	1,690
End of term fee	1,688	1,688
Lease obligations, net of current portion	9,487	9,779
Other non-current liabilities	405	419
TOTAL LIABILITIES	197,169	193,976
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 231,769,765 and 226,063,032 shares issued and outstanding at March 31, 2024 and December 31, 2023	23	23
Additional paid-in capital	642,133	641,439
Accumulated deficit	(488,450)	(506,256)
TOTAL STOCKHOLDERS' EQUITY	153,706	135,206
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 350,875	$ 329,182

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CEO	Mr. Adam S. Grossman
WEBSITE	admabiologics.com
INDUSTRY	Biotechnology
EMPLOYEES	617

ADMA Biologics Inc Frequently Asked Questions

What is the ticker symbol for ADMA Biologics Inc? What does ADMA stand for in stocks?

ADMA is the stock ticker symbol of ADMA Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ADMA Biologics Inc (ADMA)?

As of Mon May 13 2024, market cap of ADMA Biologics Inc is 2.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADMA stock?

You can check ADMA's fair value in chart for subscribers.

What is the fair value of ADMA stock?

You can check ADMA's fair value in chart for subscribers. The fair value of ADMA Biologics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ADMA Biologics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADMA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ADMA Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ADMA is over valued or under valued. Whether ADMA Biologics Inc is cheap or expensive depends on the assumptions which impact ADMA Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADMA.

What is ADMA Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, ADMA's PE ratio (Price to Earnings) is -559.14 and Price to Sales (PS) ratio is 7.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADMA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ADMA Biologics Inc's stock?

In the past 10 years, ADMA Biologics Inc has provided 0.016 (multiply by 100 for percentage) rate of return.